KRAS and neoplasm: The same 5% cut-off was obtained by analyzing deletions (i.e., EGFR p.E746_A750del, c.2235_2249del) and missense point mutations (i.e., EGFR c.2369C>T p.T790M, KRAS c.35G>A p.G12D, KRAS c.38G>A p.G13D, NRAS c.182A>T p.Q61L, BRAF c.1799T>A p.V600E, BRAF c.1798_1799GT>AA p.V600K, and PIK3CA c.3140A>G p.H1047R) using reference tumor DNA in standard paraffin embedded formats (Horizon Diagnostics [HDx], Cambridge, UK) as recently reported by our group in ring trial studies [30,31].